Latest news

The shareholders of Nanologica AB (publ), org.nr 556664-5023 (the “Company“) are hereby summoned to the Annual General Meeting on Thursday 21 May 2026, at 10.00 CET, at Advokatfirman Lindahl’s premises at Smålandsgatan 16, Stockholm. Right to attend the meeting Shareholders who wish to participate in the Annual General Meeting must: be registered in their own name in the share register maintained by Euroclear Sweden AB on Wednesday 12 May 2026, notify the Company of its

Nanologica has received an order of appx. SEK 2 million for the company’s silica-based purification media NLAB Saga®. The customer is a manufacturer of peptide drugs, and the order relates to evaluation of NLAB Saga® on a production scale. Nanologica’s team has been working with this customer for a few years, including carrying out an extensive application development project for them. With this order, the customer will proceed to evaluate NLAB Saga® on a production

We are excited to announce our participation in the upcoming Redeye Healthcare Day 2026 on 14 April 2026. Join us for live presentations on this link. Nanologica will present at 16.25.

The number of registered shares and votes in Nanologica AB has changed during the month of March as a result of the directed share issues resolved by the board of directors on 30 January 2026 and approved at the subsequent extraordinary general meeting on 4 March 2026 (the “Directed Issues”). The Directed Issues comprised a total of 34,203,780 shares, of which 31,603,780 shares have been partially registered during the month of March. The remaining 2,600,000

Over the weekend, a minor explosion occurred in an oven at a company that shares an office and laboratory corridor with Nanologica. The sprinkler system was activated automatically, and water was spread throughout the premises. No one has been injured and Nanologica’s equipment is unharmed. The initial assessment shows that none of Nanologica’s instruments or other equipment has been damaged, as water has only spread to Nanologica’s premises along the floor. The incident is under

Nanologica AB (publ) (“Nanologica” or the “Company”) today announces the outcome of the Company’s rights issue of appx. SEK 82.5 million (the “Rights Issue”), for which the subscription period ended on 25 March 2026. The Rights Issue has been subscribed to 63.3 percent with and without the support of subscription rights, of which appx. 62.7 percent was subscribed for with the support of subscription rights and appx. 0.6 percent was subscribed for without the support